A

pivotal phase 2 clinical trial designed to help Celgene (CELG) and Bluebird Bio (BLUE) secure approval for the first CAR-T therapy targeting multiple myeloma will begin enrolling patients next week.

A listing for the clinical trial of the CAR-T therapy known as BB2121 was posted to the government’s ClinicalTrials.gov website on Tuesday, with a planned start date of Dec. 11. Celgene licensed BB2121 from Bluebird and is the sponsor of the study, which the company is calling KarMMA.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to Thea Lategan Cancel reply

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.